



First patient treatments by Theraclion's Echopulse® in Poland

The Endocrine Clinic from the Holy Cross Cancer Center now offers echotherapy to their patients

Malakoff - FRANCE, December 21st, 2017 - THERACLION (Euronext Growth, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy today announced that the Endocrine Clinic of the Holy Cross Cancer Center in Kielce, Poland, invested in an Echopulse® system and started patient treatments.

The clinic is one of four in Poland offering patients with thyroid pathologies a comprehensive, interdisciplinary treatment based on surgery and iodine therapy, annually treating about 2,600 patients in the department of endocrinology. The possibility of using a non-invasive HIFU device for the treatment of benign thyroid nodules such as Echopulse® in the Holy Cross Cancer Center falls in line with the objectives of the project "Your conscious choice - a program for the prevention of head and neck cancer", co-financed by the European Social Fund. In a first step, echotherapy will be dedicated to endocrine patients with thyroid pathologies. In a second step, the program will be extended to the treatment of breast fibroadenoma.

"It was obvious that we needed to extend our care offering to be able to offer a non-invasive treatment for patients with thyroid nodules," said Pr. Aldona Kowalska, MD, PhD, Head of the Endocrinology Department in Holy Cross Cancer Center of Kielce, endocrinologist, specialist in both internal diseases and nuclear medicine. "Echopulse is a very promising, non-invasive approach of treating benign thyroid nodules. It perfectly meets our objectives to offer patients a comprehensive care program for their thyroid pathologies."

"I'm looking forward to developing, together with Theraclion, the market for non-invasive echotherapy for patients with thyroid nodules and breast fibroadenoma in Poland" said Magdalena Sierszyńska, Theraclion Authorized Representative for Poland. Synektik S.A. Poland is a partner of OncoMed Solutions, who recently acquired an Echopulse system.

"Poland is an important market in the Eastern and Central European region, with a high incidence in thyroid pathologies and rising number of thyroid surgeries in the past years," explains David Caumartin, CEO Theraclion. "We are delighted to work with the Holy Cross Cancer Center in Kielce to develop a reference centre for the region."

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 35 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com



**Theraclion is listed on Euronext Growth Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402**



Contacts :

Theraclion

David Caumartin

CEO

Tel.: +33 (0)1 55 48 90 70

david.caumartin@theraclion.com

Kalima

Press Relation

Marie Vasseur

Tel.: + 33 (0)1 42 21 56 36

mvasseur@kalima-rp.fr